# A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate

> **NCT00578305** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 185 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Rituximab
- **DRUG:** Placebo
- **DRUG:** Methylprednisolone
- **DRUG:** Methotrexate
- **DRUG:** Folic acid or folate

## Key facts

- **NCT ID:** NCT00578305
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-11
- **Final completion:** 2013-05
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2015-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00578305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00578305, "A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00578305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*